Search | Clinical Trials Finder

Conditions: Ovarian Cancer, NSCLC, ESCC, Solid Tumors
Interventions: ASP0739; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Duarte, California • Miami, Florida • Chicago, Illinois + 2 more

Conditions: Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
Interventions: Bevacizumab, FOLFIRI, Pelareorep; Drug
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 17
States / cities: Homewood, Alabama • Beverly Hills, California • Encino, California + 13 more

Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Etigilimab, Nivolumab; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Phoenix, Arizona • Greenbrae, California • Los Angeles, California + 11 more

Conditions: Prematurity, Necrotizing Enterocolitis
Interventions: [5,5,5-2H3]leucine (stable isotope labeled leucine); Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 7 Days
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Loncastuximab Tesirine, Rituximab; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 65 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 29
States / cities: Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 24 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Capsule + Powder supplementation, stable tracer infusion; Dietary Supplement · Other
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years to 100 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Interventions: 131I-MIBG, 131-MIBG + Vorinostat; Drug
Lead sponsor: Jubilant DraxImage Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 21
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 17 more

Conditions: Rheumatoid Arthritis
Interventions: methotrexate, rituximab [MabThera/Rituxan]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 59
States / cities: Mesa, Arizona • Paradise Valley, Arizona • Tucson, Arizona + 47 more

Conditions: Healthy
Interventions: C-13 labeled Lysine, Normal saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 28
States / cities: Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more

Conditions: Advanced Incurable Solid Malignancy
Interventions: Vandetanib, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Leonard Appleman; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: acute resistance exercise with oral nutrition supplementation, stable tracer infusion; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Diabetes Mellitus, Impaired Fasting Glucose, Prediabetes
Interventions: Re-infusion of biotin labeled cells, Diabetes education/diabetes medication adjustment; Biological · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dermatomyositis
Interventions: Octagam 10%, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Huntington Beach, California • Los Angeles, California • Orange, California + 14 more

Conditions: Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
Interventions: Ezabenlimab, BI 754111, BI 836880; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 11
States / cities: La Jolla, California • Fort Myers, Florida • St. Petersburg, Florida + 8 more

Conditions: Solid Neoplasms
Interventions: Dazostinag, Pembrolizumab, Platinum, 5-fluorouracil; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 26
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 20 more

Conditions: Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions: Sebelipase alfa (SBC-102); Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Up to 24 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Irvine, California

Conditions: HIV, Healthy Volunteers
Interventions: [6,6-2H2]-glucose; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC), Cervical Cancer
Interventions: AN0025, Pembrolizumab; Drug
Lead sponsor: Adlai Nortye Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: St Louis, Missouri • Houston, Texas • Salt Lake City, Utah + 1 more

Conditions: Solid Tumors
Interventions: Oleclumab, Durvalumab; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: La Jolla, California • New Haven, Connecticut • Gainesville, Florida + 8 more

Conditions: Myasthenia Gravis
Interventions: HIZENTRA ®; Drug
Lead sponsor: Mazen Dimachkie, MD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Phoenix, Arizona • Kansas City, Kansas • Buffalo, New York + 1 more

Conditions: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Interventions: KW-0761; Biological
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions: Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP); Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 30
States / cities: Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more

Conditions: Gastrointestinal Stromal Tumor
Interventions: Ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 1 more

Search by objective public record fields.

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Collaborative Research Group for Necrotizing Enterocolitis

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

Fish Oil and HMB Supplementation in COPD

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

Study of GemOx and Vandetanib in Advanced Solid Malignancy

Oral Supplement and Acute Resistance Exercise

Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)